LOGIN  |  REGISTER
Assertio

Molina Healthcare Announces Third Quarter 2025 Earnings Release and Conference Call Dates

September 03, 2025 | Last Trade: US$166.90 6.38 3.97

LONG BEACH, Calif. / Sep 03, 2025 / Business Wire / Molina Healthcare, Inc. (NYSE: MOH) today announced it will issue its earnings release for the third quarter ending September 30, 2025, after the market closes on Wednesday, October 22, 2025, and will host a conference call and webcast to discuss the earnings release on Thursday, October 23, 2025, at 8:00 a.m. Eastern Time. To access this interactive teleconference, dial (877) 883-0383 and enter the confirmation number, 2660919. A telephonic replay of the conference call will be available through Thursday, October 30, 2025, by dialing (877) 344-7529 and entering the confirmation number, 1905016.

A live broadcast of Molina Healthcare’s conference call will be available on the Company’s investor relations website, investors.molinahealthcare.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast.

About Molina Healthcare

Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. For more information about Molina Healthcare, please visit molinahealthcare.com.

Assertio

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page